Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs

Furumoto, Katsuyoshi, Soares, Luis, Engleman, Edgar G., Merad, Miriam·2004·Journal of Clinical Investigation

Abstract

Recent reports of tumor regression following delivery of autologous tumor antigen-pulsed DCs suggest that defective antigen presentation may play a key role in tumor escape. Here we show in two different murine tumor models, CT26 (colon adenocarcinoma) and B16 (melanoma), that the number and activation state of intratumoral DCs are critical factors in the host response to tumors. We used CCL20/macrophage inflammatory protein-3alpha (MIP-3alpha) chemokine to increase the number of tumoral DCs and intratumoral injections of CG-rich motifs (CpGs) to activate such cells. Expression of CCL20 in the tumor site attracted large numbers of circulating DCs into the tumor mass and, in the case of CT26 tumors, led to complete tumor regression. Intratumoral CpG injections, in addition to CCL20, were required to induce therapeutic immunity against B16 tumors. In this model CpG overcame tumor-mediated inhibition of DC activation and enabled tumoral DCs to cross-present tumor antigens to naive CD8 T cells. CpG activation of tumoral DCs alone was not sufficient to induce tumor regression in either tumor model, nor was systemic delivery of the DC growth factor, Flt3 ligand, which dramatically increased the number of circulating DCs but not the number of tumoral DCs. These results indicate that the number of tumoral DCs as well as the tumor milieu determines the ability of tumor-bearing hosts to mount an effective antitumor immune response. Our results also suggest that DCs can be manipulated in vivo without delivery of defined tumor antigens to induce a specific T cell-mediated antitumor response and provide the basis for the use of chemokines in DC-targeted clinical strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci19762

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 43

  1. 10.1038/32588 · DOI · Paper page
  2. 10.1146/annurev.immunol.18.1.767 · DOI · Paper page
  3. 10.1038/nm1096-1096 · DOI · Paper page
  4. Gabrilovich, 1997, Clin. Cancer Res., 3, 483
  5. Nestle, 1997, Am. J. Pathol., 150, 641
  6. 10.1006/scbi.2001.0400 · DOI · Paper page
  7. 10.1002/path.1344 · DOI · Paper page
  8. 10.1146/annurev.immunol.18.1.245 · DOI · Paper page
  9. 10.1084/jem.193.2.233 · DOI · Paper page
  10. 10.1182/blood.V99.5.1676 · DOI
  11. 10.1038/nm882 · DOI
  12. 10.1007/s002810000053 · DOI · Paper page
  13. 10.1126/science.286.5447.2098 · DOI · Paper page
  14. 10.1084/jem.189.3.447 · DOI · Paper page
  15. 10.1016/0092-8674(94)90169-4 · DOI · Paper page
  16. 10.1038/353180a0 · DOI · Paper page
  17. 10.1016/0092-8674(91)90462-8 · DOI · Paper page
  18. 10.1038/nm1295-1297 · DOI · Paper page
  19. McKenna, 1995, Blood., 86, 3413, 10.1182/blood.V86.9.3413.bloodjournal8693413 · DOI
  20. 10.1084/jem.184.5.1953 · DOI · Paper page
  21. 10.1074/jbc.272.9.5846 · DOI · Paper page
  22. 10.1074/jbc.272.23.14893 · DOI · Paper page
  23. 10.1016/S0014-5793(98)01450-1 · DOI
  24. 10.1084/jem.188.2.373 · DOI · Paper page
  25. Liao, 1999, J. Immunol., 162, 186, 10.4049/jimmunol.162.1.186 · DOI · Paper page
  26. 10.1084/jem.191.8.1303 · DOI · Paper page
  27. 10.1002/1521-4141(200201)32:1<104::AID-IMMU104>3.0.CO;2-C · DOI
  28. Liao, 2002, J. Immunol., 168, 4871, 10.4049/jimmunol.168.10.4871 · DOI
  29. 10.1084/jem.191.8.1381 · DOI · Paper page
  30. 10.1172/JCI7548 · DOI · Paper page
  31. 10.1046/j.1365-2567.2000.00964.x · DOI
  32. Datta, 2003, J. Immunol., 170, 4102, 10.4049/jimmunol.170.8.4102 · DOI · Paper page
  33. 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J · DOI · Paper page
  34. 10.1038/75365 · DOI · Paper page
  35. Steinbrink, 1997, J. Immunol., 159, 4772, 10.4049/jimmunol.159.10.4772 · DOI · Paper page
  36. 10.1146/annurev.immunol.16.1.137 · DOI · Paper page
  37. Kawarada, 2001, J. Immunol., 167, 5247, 10.4049/jimmunol.167.9.5247 · DOI · Paper page
  38. Ballas, 2001, J. Immunol., 167, 4878, 10.4049/jimmunol.167.9.4878 · DOI · Paper page
  39. Vicari, 2000, J. Immunol., 165, 1992, 10.4049/jimmunol.165.4.1992 · DOI
  40. Salcedo, 2000, Blood., 96, 34, 10.1182/blood.V96.1.34 · DOI · Paper page
  41. 10.1038/nm0697-625 · DOI · Paper page
  42. 10.1002/(SICI)1097-0215(20000615)86:6<827::AID-IJC11>3.0.CO;2-R · doi:10.1002/(sici)1097-0215(20000615)86:6<827::aid-ijc11>3.0.co;2-r
  43. Chen, 1997, Cancer Res., 57, 3511

Cited by

See all 184

Metadata

Authors
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M.
Venue
Journal of Clinical Investigation
Published
2004-03-01
Volume
113
Issue
5
Pages
774-783
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2165123753
Cited by
184
References
3
FWCI
7.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. https://app.cochat.ai/papers/10.1172/jci19762
The paper
Furumoto, K., Soares, L., Engleman, E. G., & Merad, M. (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. Journal of Clinical Investigation. https://doi.org/10.1172/jci19762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.